{
    "clinical_study": {
        "@rank": "89059", 
        "arm_group": {
            "arm_group_label": "Breast cancer patients", 
            "description": "All patients planned to initiate hormonal therapy with either Tamoxifen, Raloxifene (Evista\u00ae), Anastrozole (Arimidex\u00ae), Letrozole (Femara\u00ae) or Exemestane (Aromasin\u00ae) are eligible to participate in sample collection and data for patient-reported outcomes/questionnaires."
        }, 
        "biospec_descr": {
            "textblock": "Blood (for example:  serum, plasma, and whole blood) and saliva samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this project is to establish a repository of information and samples from\n      breast cancer patients or those at high risk of developing breast cancer, who are initiating\n      hormone therapy as part of standard clinical care or prevention. This repository will\n      include patient reported outcomes and other questionnaires, information on medication use,\n      data about adherence to the hormone therapy and tumor characteristics, including\n      prospectively collected samples."
        }, 
        "brief_title": "Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database", 
        "completion_date": {
            "#text": "January 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This research is being done to learn more about the side effects of breast cancer hormone\n      therapy and if a person's genetic information may help us to develop a way to predict the\n      side effects a patient may have and how best to treat them.  In addition, the investigators\n      hope to look at how the side effects from hormone therapy influence a patient's willingness\n      to continue hormonal treatment.\n\n      Men and women being prescribed hormone therapies including Tamoxifen, Raloxifene (Evista),\n      Anastrozole (Arimidex), Letrozole  (Femara), or Exemestane (Aromasin), by their oncologist\n      for either prevention of breast cancer or treatment of breast cancer may join.\n\n      The decision of which hormone therapy to receive is the decision of the patient and\n      physician, this study will collect samples and patient-reported outcomes during this\n      routine, standard of care and will not direct any treatment decisions or interventions in\n      any way."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female\n\n          -  18 years of age or older\n\n          -  Physically and cognitively able to complete the questionnaires\n\n          -  Meet one of the following categories:  1) Initiating hormonal therapy for breast\n             cancer prevention. All patients planned to initiate hormonal therapy with either\n             Tamoxifen, Raloxifene (Evista\u00ae), Anastrozole (Arimidex\u00ae), Letrozole (Femara\u00ae) or\n             Exemestane (Aromasin\u00ae) are eligible; concomitant use of Zoladex or Lupron is\n             permitted; 2) Patients with histologically proven ductal carcinoma in situ\n             (DCIS/stage 0) or stage I-III invasive carcinoma of the breast that is estrogen (ER)\n             and/or progesterone (PR) positive by immunohistochemical staining, who are\n             considering one of the above listed SERMs or AIs. These patients must have completed\n             any planned chemotherapy and local therapy (e.g., lumpectomy or mastectomy); however,\n             enrollment/initiation of hormonal therapy on study may be done prior to completion of\n             radiation and/or biologic therapy (e.g., trastuzumab) at the discretion of the\n             treating team; or, 3) The patient is aware of the nature of her diagnosis,\n             understands the study regimen, its requirements, risks, and discomforts, and is able\n             and willing to sign an informed consent form.\n\n          -  Patients transitioning from one hormonal agent listed above to another may be\n             enrolled prior to initiation of the new medication.\n\n        Exclusion Criteria:\n\n          -  N/A"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Men and women being prescribed hormone therapies including Tamoxifen, Raloxifene (Evista),\n        Anastrozole (Arimidex), Letrozole  (Femara), or Exemestane (Aromasin), by their oncologist\n        for either prevention of breast cancer or treatment of breast cancer may join."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937052", 
            "org_study_id": "J1189", 
            "secondary_id": "SKCCC J1189"
        }, 
        "intervention": [
            {
                "arm_group_label": "Breast cancer patients", 
                "description": "Participants will be offered the option to consent for blood (preferred) or saliva for DNA pharmacogenetic testing, and for additional samples for banking for future studies.", 
                "intervention_name": "Sample collection", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Breast cancer patients", 
                "description": "Patient reported outcomes (PROs) will be collected via electronic questionnaires that will be administered to patients at regular intervals per the study calendar; in most cases, this should coincide with medical oncology follow-up.", 
                "intervention_name": "Patient-reported outcomes", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 14, 2014", 
        "location": {
            "contact": {
                "email": "HopkinsBreastTrials@jhmi.edu", 
                "last_name": "Hopkins Breast Trials", 
                "phone": "410-955-8804"
            }, 
            "contact_backup": {
                "email": "jhcccro@jhmi.edu", 
                "last_name": "Kimmel Cancer Center Clinical Research Office", 
                "phone": "410-955-8866"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21287-0013"
                }, 
                "name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database", 
        "overall_official": {
            "affiliation": "Sidney Kimmel Comprehensive Cancer Center", 
            "last_name": "Vered Stearns, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2022", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To collect high quality prospective data regarding individual genetic profiles, medication use and patient reported outcomes on hormone therapy, which can be used to validate correlations that have been observed in other studies", 
            "measure": "Sample and data collection", 
            "safety_issue": "No", 
            "time_frame": "10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937052"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}